Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Read more

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Read more

IPO

IPO Calliditas Therapeutics

Read more

Press releases

• Dec 14, 2018Bulletin from extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)
• Nov 14, 2018Notice of extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)
• Nov 13, 2018First patient enrolled in pivotal clinical phase 3 study NEFIGARD with lead candidate Nefecon

All press releases

Interim Report Q3 2018

On November 1, 2018, Calliditas Therapeutics published its interim report for the third quarter of 2018.

• Report
• Press release
• Presentation
• Audio cast

Read the report

Calendar

• Feb 7, 2019Year-end report for the period January 1 – December 31, 2018
• May 8, 2019Annual general meeting 2019
• May 8, 2019Interim report for the period January 1 – March 31, 2019

All events